4D Molecular Therapeutics, Inc. $FDMT Shares Acquired by BVF Inc. IL

Key Points

• BVF Inc. IL significantly increased its holdings in 4D Molecular Therapeutics by 70.8%, owning 4,561,289 shares valued at approximately $14.7 million, which constitutes 0.6% of its total portfolio.
• Several hedge funds, including Millennium Management LLC and Two Sigma Investments LP, also raised their positions in 4D Molecular Therapeutics, with some increasing holdings by over 1,600% in the last quarter.
• 4D Molecular Therapeutics recently reported a loss of $0.98 EPS, missing expectations, and had a negative return on equity of 40.15%, with projected earnings of -2.84 EPS for the current fiscal year.

BVF Inc. IL boosted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 70.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,561,289 shares of the company's stock after purchasing an additional 1,890,647 shares during the quarter. 4D Molecular Therapeutics comprises approximately 0.6% of BVF Inc. IL's portfolio, making the stock its 28th biggest holding. BVF Inc. IL owned approximately 9.85% of 4D Molecular Therapeutics worth $14,733,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in 4D Molecular Therapeutics during the fourth quarter valued at approximately $50,000. Velan Capital Investment Management LP bought a new position in 4D Molecular Therapeutics during the fourth quarter valued at approximately $56,000. Y Intercept Hong Kong Ltd bought a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $41,000. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. Finally, ProShare Advisors LLC grew its position in 4D Molecular Therapeutics by 30.1% during the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock valued at $91,000 after acquiring an additional 3,783 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on FDMT shares. Roth Capital lowered their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Saturday, August 30th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Stock Up 10.0%

Shares of FDMT stock traded up $0.66 during mid-day trading on Friday, reaching $7.27. 764,947 shares of the company's stock traded hands, compared to its average volume of 712,914. 4D Molecular Therapeutics, Inc. has a 12 month low of $2.23 and a 12 month high of $17.41. The company has a market cap of $339.52 million, a P/E ratio of -2.06 and a beta of 2.86. The company's 50-day moving average price is $5.41 and its 200-day moving average price is $4.27.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. Equities analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.